Letter to the Editor
Acneiform Eruption Secondary to Cetuximab With Pseudomalignant Histopathological Changes
Leído
6160
Vecesse ha leído el artículo
2736
Total PDF
3424
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 17 | 6 | 23 |
| 2025 5 | 76 | 29 | 105 |
| 2025 4 | 96 | 16 | 112 |
| 2025 3 | 77 | 21 | 98 |
| 2025 2 | 72 | 32 | 104 |
| 2025 1 | 58 | 22 | 80 |
| 2024 12 | 68 | 27 | 95 |
| 2024 11 | 70 | 54 | 124 |
| 2024 10 | 67 | 49 | 116 |
| 2024 9 | 53 | 40 | 93 |
| 2024 8 | 79 | 75 | 154 |
| 2024 7 | 57 | 32 | 89 |
| 2024 6 | 55 | 38 | 93 |
| 2024 5 | 44 | 32 | 76 |
| 2024 4 | 39 | 40 | 79 |
| 2024 3 | 61 | 40 | 101 |
| 2024 2 | 44 | 34 | 78 |
| 2024 1 | 36 | 44 | 80 |
| 2023 12 | 49 | 34 | 83 |
| 2023 11 | 31 | 29 | 60 |
| 2023 10 | 31 | 35 | 66 |
| 2023 9 | 29 | 21 | 50 |
| 2023 8 | 24 | 26 | 50 |
| 2023 7 | 49 | 56 | 105 |
| 2023 6 | 52 | 26 | 78 |
| 2023 5 | 29 | 28 | 57 |
| 2023 4 | 25 | 19 | 44 |
| 2023 3 | 36 | 29 | 65 |
| 2023 2 | 16 | 20 | 36 |
| 2022 1 | 39 | 31 | 70 |
| 2022 12 | 23 | 41 | 64 |
| 2022 11 | 24 | 38 | 62 |
| 2022 10 | 19 | 24 | 43 |
| 2022 9 | 12 | 29 | 41 |
| 2022 8 | 12 | 50 | 62 |
| 2022 7 | 24 | 32 | 56 |
| 2022 6 | 16 | 21 | 37 |
| 2022 5 | 22 | 35 | 57 |
| 2022 4 | 32 | 31 | 63 |
| 2022 3 | 22 | 38 | 60 |
| 2022 2 | 22 | 23 | 45 |
| 2021 1 | 18 | 35 | 53 |
| 2021 12 | 10 | 39 | 49 |
| 2021 11 | 20 | 42 | 62 |
| 2021 10 | 21 | 35 | 56 |
| 2021 9 | 9 | 35 | 44 |
| 2021 8 | 18 | 22 | 40 |
| 2021 7 | 17 | 32 | 49 |
| 2021 6 | 16 | 35 | 51 |
| 2021 5 | 9 | 19 | 28 |
| 2021 4 | 50 | 31 | 81 |
| 2021 3 | 36 | 31 | 67 |
| 2021 2 | 43 | 23 | 66 |
| 2020 1 | 22 | 19 | 41 |
| 2020 12 | 18 | 12 | 30 |
| 2020 11 | 7 | 18 | 25 |
| 2020 10 | 12 | 6 | 18 |
| 2020 9 | 15 | 6 | 21 |
| 2020 8 | 23 | 25 | 48 |
| 2020 7 | 25 | 7 | 32 |
| 2020 6 | 12 | 29 | 41 |
| 2020 5 | 18 | 15 | 33 |
| 2020 4 | 19 | 12 | 31 |
| 2020 3 | 17 | 24 | 41 |
| 2020 2 | 1 | 2 | 3 |
| 2020 1 | 1 | 1 | 2 |
| 2019 12 | 0 | 11 | 11 |
| 2019 11 | 0 | 1 | 1 |
| 2019 10 | 0 | 1 | 1 |
| 2019 9 | 0 | 2 | 2 |
| 2019 8 | 0 | 2 | 2 |
| 2019 7 | 0 | 8 | 8 |
| 2019 6 | 0 | 2 | 2 |
| 2019 5 | 1 | 43 | 44 |
| 2019 4 | 0 | 1 | 1 |
| 2019 3 | 0 | 2 | 2 |
| 2019 2 | 0 | 1 | 1 |
| 2019 1 | 0 | 3 | 3 |
| 2018 2 | 10 | 3 | 13 |
| 2018 1 | 13 | 4 | 17 |
| 2017 12 | 16 | 8 | 24 |
| 2017 11 | 9 | 2 | 11 |
| 2017 10 | 9 | 7 | 16 |
| 2017 9 | 14 | 7 | 21 |
| 2017 8 | 9 | 14 | 23 |
| 2017 7 | 8 | 6 | 14 |
| 2017 6 | 11 | 50 | 61 |
| 2017 5 | 14 | 9 | 23 |
| 2017 4 | 17 | 9 | 26 |
| 2017 3 | 16 | 47 | 63 |
| 2017 2 | 16 | 6 | 22 |
| 2016 1 | 9 | 4 | 13 |
| 2016 12 | 18 | 5 | 23 |
| 2016 11 | 22 | 7 | 29 |
| 2016 10 | 21 | 16 | 37 |
| 2016 9 | 23 | 8 | 31 |
| 2016 8 | 19 | 4 | 23 |
| 2016 7 | 17 | 20 | 37 |
| 2016 6 | 6 | 7 | 13 |
| 2016 5 | 6 | 5 | 11 |
| 2016 4 | 7 | 13 | 20 |
| 2016 3 | 3 | 11 | 14 |
| 2016 2 | 5 | 10 | 15 |
| 2015 1 | 9 | 8 | 17 |
| 2015 12 | 6 | 9 | 15 |
| 2015 11 | 15 | 9 | 24 |
| 2015 10 | 6 | 3 | 9 |
| 2015 9 | 6 | 35 | 41 |
| 2015 8 | 11 | 4 | 15 |
| 2015 7 | 21 | 3 | 24 |
| 2015 6 | 20 | 2 | 22 |
| 2015 5 | 40 | 13 | 53 |
| 2015 4 | 27 | 8 | 35 |
| 2015 3 | 33 | 3 | 36 |
| 2015 2 | 25 | 6 | 31 |
| 2015 1 | 14 | 13 | 27 |
| 2014 12 | 20 | 12 | 32 |
| 2014 11 | 20 | 13 | 33 |
| 2014 10 | 33 | 16 | 49 |
| 2014 9 | 27 | 13 | 40 |
| 2014 8 | 35 | 17 | 52 |
| 2014 7 | 42 | 24 | 66 |
| 2014 6 | 42 | 12 | 54 |
| 2014 5 | 43 | 13 | 56 |
| 2014 4 | 33 | 6 | 39 |
| 2014 3 | 55 | 17 | 72 |
| 2014 2 | 33 | 12 | 45 |
| 2014 1 | 39 | 18 | 57 |
| 2013 12 | 31 | 11 | 42 |
| 2013 11 | 25 | 15 | 40 |
| 2013 10 | 23 | 16 | 39 |
| 2013 9 | 32 | 17 | 49 |
| 2013 8 | 26 | 13 | 39 |
| 2013 7 | 21 | 29 | 50 |
| 2013 6 | 18 | 21 | 39 |
| 2013 5 | 25 | 17 | 42 |
| 2013 4 | 25 | 17 | 42 |
| 2013 3 | 26 | 19 | 45 |
| 2013 2 | 23 | 8 | 31 |
| 2013 1 | 11 | 3 | 14 |
Mostrar todo
